|
| 37191222 | A Phase 1 First-in-Human Single-Ascending-Dose Trial With ESB1609, a Selective Agonist to the Sphingosine-1-Phosphate Receptor 5. | Clin Pharmacol Drug Dev | 2023 |
| 33836114 | Differential Inhibition of LRRK2 in Parkinson's Disease Patient Blood by a G2019S Selective LRRK2 Inhibitor. | Mov Disord | 2021 |
| 30642435 | "Alzheimer's disease" is neither "Alzheimer's clinical syndrome" nor "dementia". | Alzheimers Dement | 2019 |
| 29429971 | Biomarker pattern of ARIA-E participants in phase 3 randomized clinical trials with bapineuzumab. | Neurology | 2018 |
| 29914022 | Long-Term Follow Up of Patients with Mild-to-Moderate Alzheimer's Disease Treated with Bapineuzumab in a Phase III, Open-Label, Extension Study. | J Alzheimers Dis | 2018 |
| 30298182 | Psychometric Evaluation of the Neuropsychological Test Battery in Individuals with Normal Cognition, Mild Cognitive Impairment, or Mild to Moderate Alzheimer's Disease: Results from a Longitudinal Study. | J Prev Alzheimers Dis | 2018 |
| 29653606 | NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease. | Alzheimers Dement | 2018 |
| 28124589 | Long-Term Extensions of Randomized Vaccination Trials of ACC-001 and QS-21 in Mild to Moderate Alzheimer's Disease. | Curr Alzheimer Res | 2017 |
| 28386518 | Outcomes Assessment in Clinical Trials of Alzheimer's Disease and its Precursors: Readying for Short-term and Long-term Clinical Trial Needs. | Innov Clin Neurosci | 2017 |
| 25669746 | Amyloid-related imaging abnormalities-haemosiderin (ARIA-H) in patients with Alzheimer's disease treated with bapineuzumab: a historical, prospective secondary analysis. | J Neurol Neurosurg Psychiatry | 2016 |
| 29210443 | Vanutide Cridificar (ACC-001) and QS-21 Adjuvant in Individuals with Early Alzheimer's Disease: Amyloid Imaging Positron Emission Tomography and Safety Results from a Phase 2 Study. | J Prev Alzheimers Dis | 2016 |
| 29199321 | A Randomized, Double-Blind, Phase 2 Study of the Effects of the Vaccine Vanutide Cridificar with QS-21 Adjuvant on Immunogenicity, Safety and Amyloid Imaging in Patients with Mild to Moderate Alzheimer's Disease. | J Prev Alzheimers Dis | 2016 |
| 29067308 | Profiling the dynamics of CSF and plasma Aβ reduction after treatment with JNJ-54861911, a potent oral BACE inhibitor. | Alzheimers Dement (N Y) | 2016 |
| 26639957 | Changes in Brain Volume with Bapineuzumab in Mild to Moderate Alzheimer's Disease. | J Alzheimers Dis | 2016 |
| 27589523 | A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Safety, Pharmacokinetics, and Biomarker Results of Subcutaneous Bapineuzumab in Patients with mild to moderate Alzheimer's disease. | J Alzheimers Dis | 2016 |
| 27163805 | Biomarker Exposure-Response Analysis in Mild-To-Moderate Alzheimer's Disease Trials of Bapineuzumab. | J Alzheimers Dis | 2016 |
| 26967206 | Two Phase 2 Multiple Ascending-Dose Studies of Vanutide Cridificar (ACC-001) and QS-21 Adjuvant in Mild-to-Moderate Alzheimer's Disease. | J Alzheimers Dis | 2016 |
| 26925577 | First-In-Human safety and long-term exposure data for AAB-003 (PF-05236812) and biomarkers after intravenous infusions of escalating doses in patients with mild to moderate Alzheimer's disease. | Alzheimers Res Ther | 2016 |
| 25708309 | Building a roadmap for developing combination therapies for Alzheimer's disease. | Expert Rev Neurother | 2015 |
| 27239522 | Revolutionizing Alzheimer's disease and clinical trials through biomarkers. | Alzheimers Dement (Amst) | 2015 |
| 26208959 | Amyloid-β 11C-PiB-PET imaging results from 2 randomized bapineuzumab phase 3 AD trials. | Neurology | 2015 |
| 26194317 | Perspective: The Alzheimer's Disease Neuroimaging Initiative and the role and contributions of the Private Partner Scientific Board (PPSB). | Alzheimers Dement | 2015 |
| 24092460 | Genetic analysis of quantitative phenotypes in AD and MCI: imaging, cognition and biomarkers. | Brain Imaging Behav | 2014 |
| 24521259 | Cognition in MCI and Alzheimer's disease: baseline data from a longitudinal study of the NTB. | Clin Neuropsychol | 2014 |
| 24450891 | Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease. | N Engl J Med | 2014 |
| 23932184 | The Alzheimer's Disease Neuroimaging Initiative: a review of papers published since its inception. | Alzheimers Dement | 2013 |
| 24154646 | Association between illness progression measures and total cost in Alzheimer's disease. | J Nutr Health Aging | 2013 |
| 22047634 | The Alzheimer's Disease Neuroimaging Initiative: a review of papers published since its inception. | Alzheimers Dement | 2012 |
| 22473769 | Effect of immunotherapy with bapineuzumab on cerebrospinal fluid biomarker levels in patients with mild to moderate Alzheimer disease. | Arch Neurol | 2012 |
| 22305802 | Amyloid-related imaging abnormalities in patients with Alzheimer's disease treated with bapineuzumab: a retrospective analysis. | Lancet Neurol | 2012 |
| 22292124 | Targeting Beta amyloid: a clinical review of immunotherapeutic approaches in Alzheimer's disease. | Int J Alzheimers Dis | 2012 |
| 22343285 | Association of common genetic variants in GPCPD1 with scaling of visual cortical surface area in humans. | Proc Natl Acad Sci U S A | 2012 |
| 20189881 | 11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study. | Lancet Neurol | 2010 |
| 19923550 | A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease. | Neurology | 2009 |